Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.

Alumis Inc. Common Stock

A company that transforms the lives of patients living with immune-mediated diseases using a precision approach to develop oral therapies.

Alumis

At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.

We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. 

Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. 

Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.

Today we announced the pricing of our initial public offering: https://bit.ly/3zwhdvh #NasdaqListed

Today, we honor #Juneteenth, celebrating freedom, resilience, and progress. As we reflect on this important day in history, we’re committed to fostering diversity and inclusion at Alumis. #FreedomDay

Alumis’ clinical development team attended the EULAR - European Alliance of Associations for Rheumatology 2024 Congress earlier this month in Vienna! With the goal of driving progress in the clinical care of people with rheumatic diseases, the annual meeting brings together patients, health professionals, rheumatologists and industry partners to showcase the latest scientific breakthroughs in clinical, translational, and basic research. We were thrilled to be part of this meeting as we advance our #lupus clinical trial LUMUS! #EULAR2024

This #PrideMonth, we celebrate the vibrant LGBTQIA+ community and recognize their invaluable contributions to science and biotechnology. Together, we stand proud in our commitment to diversity, inclusion, and equality. #Pride2024

Did you know that women are disproportionately affected by #lupus? To learn more about lupus this #LupusAwarenessMonth, check out resources and information from @LupusResearch: https://lnkd.in/esmUVvvw

We are thrilled to announce our initial public offering, trading on Nasdaq under the ticker $ALMS! This achievement wouldn't have been possible without the relentless dedication of our incredible team, as well as the support of our Board of Directors and investors. Thank you to everyone who helped us reach this critical milestone in support of our mission to improve the lives of patients with immune-mediated diseases. #NasdaqListed

	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24	Jun '24
net income	-36.03M -	-36.29M 0.73%	-43.38M 19.53%	-39.30M 9.40%	-49.85M 26.84%	-56.51M 13.36%
depreciation and amortization	120K -	120K 0%	318K 165%	726K 128.30%	758K 4.41%	760K 0.26%
deferred income tax
stock based compensation	1.83M -		2.27M -	2.62M 15.20%	2.66M 1.61%
change in working capital	-1.09M -	5.81M 632.66%	5.68M 2.17%	1.66M 70.74%	-886K 153.31%	-1.53M 72.57%
accounts receivables
inventory
accounts payables	63K -		1.98M -	-3.29M 266.09%	5.71M 273.87%
other working capital	-1.09M -	5.81M 632.66%	3.70M 36.26%	4.95M 33.72%	-886K 117.90%	-1.53M 72.57%
other non cash items	2.57M -	2.27M 11.68%	1.86M 17.89%	570K 69.40%	7.23M 1,168.60%	6.51M 9.96%
net cash provided by operating activities	-34.67M -	-28.33M 18.27%	-33.25M 17.34%	-33.73M 1.45%	-44.26M 31.24%	-52.29M 18.13%
investments in property plant and equipment	-295K -	-825K 179.66%	-2.17M 162.91%	-1.21M 44.21%	-155K 87.19%	-432K 178.71%
acquisitions net
purchases of investments	-4.89M -	-3.45M 29.45%	-5K 99.86%	-2.93M 58,580.00%	-19.66M 569.90%	-39.31M 99.99%
sales maturities of investments	36.25M -	30.25M 16.55%	9.75M 67.77%		1M -	7M 600%
other investing activites
net cash used for investing activites	31.07M -	25.98M 16.38%	7.58M 70.83%	-4.14M 154.70%	-18.81M 353.91%	-32.74M 74.06%
debt repayment
common stock issued		59.96M -			129.15M -	129.85M 0.55%
common stock repurchased	-51K -
dividends paid
other financing activites			47K -	-263K 659.57%		-1.79M -
net cash used provided by financing activities	-51K -	59.96M 117,672.55%	47K 99.92%	29.72M 63,142.55%	129.15M 334.49%	128.06M 0.84%
effect of forex changes on cash
net change in cash	-3.65M -	57.60M 1,676.44%	-25.62M 144.48%	-8.15M 68.20%	65.05M 898.47%	43.04M 33.84%
cash at beginning of period	26.95M -		80.90M -	55.28M 31.67%	47.13M 14.74%	112.18M 138.02%
cash at end of period	23.30M -	57.60M 147.22%	55.28M 4.03%	47.13M 14.74%	112.18M 138.02%	155.22M 38.36%
operating cash flow	-34.67M -	-28.33M 18.27%	-33.25M 17.34%	-33.73M 1.45%	-44.26M 31.24%	-52.29M 18.13%
capital expenditure	-295K -	-825K 179.66%	-2.17M 162.91%	-1.21M 44.21%	-155K 87.19%	-432K 178.71%
free cash flow	-34.96M -	-29.16M 16.60%	-35.41M 21.45%	-34.94M 1.35%	-44.42M 27.13%	-52.72M 18.69%

ALMS

COM:ALUMIS

Alumis

Last Close

9.44

22/11 21:00

Market Cap

514.69M

Beta: -

Volume Today

115.52K

Avg: -

Preview